Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil

Ilona Benko, Katayoun Djazayeri, C. Ábrahám, Judit Zsuga, Z. Szilvássy

Research output: Article

10 Citations (Scopus)

Abstract

Insulin promotes survival of haemopoietic progenitors. We investigated if rosiglitazone, an insulin sensitizer, could confer protection against 5-fluorouracil (5-FU)-induced myelotoxicity in mice. The decrease in bone marrow cellularity, frequency and content of granulocyte-macrophage progenitors (CFU-GM) characterized myelotoxicity in mice, while insulin sensitivity was determined by hyperinsulinaemic euglycaemic glucose clamping. CFU-GM colony numbers increased in groups pre-treated with rosiglitazone (1.5-6 mg/kg, 5 days), compared to that in mice treated with 5-fluorouracil alone. Since rosiglitazone pre-treatment significantly promoted the clonal expansion of CFU-GM when given in the insulin sensitizing dose, we conclude that rosiglitazone had myeloprotective effects possibly by amplifying endogenous insulin action.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalEuropean Journal of Pharmacology
Volume477
Issue number2
DOIs
Publication statusPublished - szept. 12 2003

Fingerprint

rosiglitazone
Granulocyte-Macrophage Progenitor Cells
Fluorouracil
Insulin
Glucose Clamp Technique
Insulin Resistance
Bone Marrow

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. / Benko, Ilona; Djazayeri, Katayoun; Ábrahám, C.; Zsuga, Judit; Szilvássy, Z.

In: European Journal of Pharmacology, Vol. 477, No. 2, 12.09.2003, p. 179-182.

Research output: Article

@article{0d291962699d4715a0812b5f096b2f00,
title = "Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil",
abstract = "Insulin promotes survival of haemopoietic progenitors. We investigated if rosiglitazone, an insulin sensitizer, could confer protection against 5-fluorouracil (5-FU)-induced myelotoxicity in mice. The decrease in bone marrow cellularity, frequency and content of granulocyte-macrophage progenitors (CFU-GM) characterized myelotoxicity in mice, while insulin sensitivity was determined by hyperinsulinaemic euglycaemic glucose clamping. CFU-GM colony numbers increased in groups pre-treated with rosiglitazone (1.5-6 mg/kg, 5 days), compared to that in mice treated with 5-fluorouracil alone. Since rosiglitazone pre-treatment significantly promoted the clonal expansion of CFU-GM when given in the insulin sensitizing dose, we conclude that rosiglitazone had myeloprotective effects possibly by amplifying endogenous insulin action.",
keywords = "Bone marrow toxicity, CFU-GM, Insulin sensitizer, Thiazolidinedione",
author = "Ilona Benko and Katayoun Djazayeri and C. {\'A}brah{\'a}m and Judit Zsuga and Z. Szilv{\'a}ssy",
year = "2003",
month = "9",
day = "12",
doi = "10.1016/j.ejphar.2003.08.021",
language = "English",
volume = "477",
pages = "179--182",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil

AU - Benko, Ilona

AU - Djazayeri, Katayoun

AU - Ábrahám, C.

AU - Zsuga, Judit

AU - Szilvássy, Z.

PY - 2003/9/12

Y1 - 2003/9/12

N2 - Insulin promotes survival of haemopoietic progenitors. We investigated if rosiglitazone, an insulin sensitizer, could confer protection against 5-fluorouracil (5-FU)-induced myelotoxicity in mice. The decrease in bone marrow cellularity, frequency and content of granulocyte-macrophage progenitors (CFU-GM) characterized myelotoxicity in mice, while insulin sensitivity was determined by hyperinsulinaemic euglycaemic glucose clamping. CFU-GM colony numbers increased in groups pre-treated with rosiglitazone (1.5-6 mg/kg, 5 days), compared to that in mice treated with 5-fluorouracil alone. Since rosiglitazone pre-treatment significantly promoted the clonal expansion of CFU-GM when given in the insulin sensitizing dose, we conclude that rosiglitazone had myeloprotective effects possibly by amplifying endogenous insulin action.

AB - Insulin promotes survival of haemopoietic progenitors. We investigated if rosiglitazone, an insulin sensitizer, could confer protection against 5-fluorouracil (5-FU)-induced myelotoxicity in mice. The decrease in bone marrow cellularity, frequency and content of granulocyte-macrophage progenitors (CFU-GM) characterized myelotoxicity in mice, while insulin sensitivity was determined by hyperinsulinaemic euglycaemic glucose clamping. CFU-GM colony numbers increased in groups pre-treated with rosiglitazone (1.5-6 mg/kg, 5 days), compared to that in mice treated with 5-fluorouracil alone. Since rosiglitazone pre-treatment significantly promoted the clonal expansion of CFU-GM when given in the insulin sensitizing dose, we conclude that rosiglitazone had myeloprotective effects possibly by amplifying endogenous insulin action.

KW - Bone marrow toxicity

KW - CFU-GM

KW - Insulin sensitizer

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=1642267451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642267451&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2003.08.021

DO - 10.1016/j.ejphar.2003.08.021

M3 - Article

C2 - 14519422

AN - SCOPUS:1642267451

VL - 477

SP - 179

EP - 182

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -